DE602004028610D1 - Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen - Google Patents

Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen

Info

Publication number
DE602004028610D1
DE602004028610D1 DE602004028610T DE602004028610T DE602004028610D1 DE 602004028610 D1 DE602004028610 D1 DE 602004028610D1 DE 602004028610 T DE602004028610 T DE 602004028610T DE 602004028610 T DE602004028610 T DE 602004028610T DE 602004028610 D1 DE602004028610 D1 DE 602004028610D1
Authority
DE
Germany
Prior art keywords
durability
stability
improving
liposome complexes
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004028610T
Other languages
English (en)
Inventor
Esther H Chang
Kathleen F Pirollo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of DE602004028610D1 publication Critical patent/DE602004028610D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602004028610T 2003-06-04 2004-06-04 Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen Active DE602004028610D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47550003P 2003-06-04 2003-06-04
PCT/US2004/017695 WO2005000271A1 (en) 2003-06-04 2004-06-04 Method for improving stability and shelf-life of liposome complexes

Publications (1)

Publication Number Publication Date
DE602004028610D1 true DE602004028610D1 (de) 2010-09-23

Family

ID=33551542

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028610T Active DE602004028610D1 (de) 2003-06-04 2004-06-04 Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen

Country Status (14)

Country Link
US (1) US20050002998A1 (de)
EP (1) EP1633327B1 (de)
JP (2) JP4987474B2 (de)
CN (2) CN1798545B (de)
AT (1) ATE476964T1 (de)
AU (1) AU2004251680B2 (de)
CA (1) CA2528411C (de)
DE (1) DE602004028610D1 (de)
DK (1) DK1633327T3 (de)
ES (1) ES2350485T3 (de)
HK (2) HK1086202A1 (de)
PL (1) PL1633327T3 (de)
PT (1) PT1633327E (de)
WO (1) WO2005000271A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
JP4571514B2 (ja) * 2005-01-21 2010-10-27 ポーラ化成工業株式会社 ベシクル系外用組成物
WO2006119121A2 (en) * 2005-04-29 2006-11-09 University Of Louisville Research Foundation, Inc. Cell-surface decoration with active agents
CA2638899C (en) * 2005-10-20 2016-01-05 Georgetown University Tumor-targeted nanodelivery systems to improve early mri detection of cancer
CA2652222A1 (en) * 2006-05-15 2007-12-13 Georgetown University Preparation of antibody- or antibody-fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
EP2022853A4 (de) * 2006-05-17 2010-03-10 Yoshiyuki Koyama Gefriergetrocknetes produkt zur überführung von nukleinsäure, oligonukleinsäure oder einem derivat davon
JP5973121B2 (ja) 2007-01-30 2016-08-23 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 生体内分解性ラッピングおよびその使用
WO2009009054A1 (en) 2007-07-09 2009-01-15 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
WO2011038068A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
JP2013509258A (ja) 2009-10-28 2013-03-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 生体浸食性ラップおよびそのための使用
CA2785989A1 (en) 2009-12-31 2011-07-07 Neograft Technologies, Inc. Graft devices and methods of fabrication
CA2795765C (en) 2010-04-06 2020-07-07 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
WO2012012407A2 (en) 2010-07-19 2012-01-26 Neograft Technologies, Inc. Graft devices and methods of use
US9579224B2 (en) 2011-07-25 2017-02-28 Neograft Technologies, Inc. Vessel remodeling methods and devices for use in a graft device
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
BR102013004109A2 (pt) 2012-09-19 2015-06-23 Univ Georgetown Lipossomas direcionados
US9878055B2 (en) 2013-03-14 2018-01-30 Georgetown University Treatment for exposure to nerve agent
US10676746B2 (en) 2013-11-22 2020-06-09 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating monitoring cancers
JP2017537630A (ja) * 2014-12-03 2017-12-21 カプリコール，インコーポレイテッド 低酸素培養条件におけるエクソソームの生成方法
DK3324932T3 (da) * 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN109562067A (zh) * 2016-08-02 2019-04-02 库里尔克思股份有限公司 制备脂质体的方法
SG11202002579SA (en) * 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
JPH01106829A (ja) * 1987-10-21 1989-04-24 Tosoh Corp スーパーオキサイドジスムターゼ保持リポソーム製剤の凍結乾燥法
WO1993020802A1 (en) * 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
EP1491217A1 (de) * 1995-06-07 2004-12-29 The Regents Of The University Of California Stabilisierung von Polynukleotidkomplexen
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
CN1191094C (zh) * 1997-11-19 2005-03-02 乔治敦大学 定向脂质体基因送递
ATE511543T1 (de) * 1999-02-22 2011-06-15 Univ Georgetown Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung
JP2001002592A (ja) * 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine

Also Published As

Publication number Publication date
AU2004251680B2 (en) 2010-02-18
AU2004251680A1 (en) 2005-01-06
CN103251562A (zh) 2013-08-21
CN1798545A (zh) 2006-07-05
HK1188147A1 (zh) 2014-04-25
US20050002998A1 (en) 2005-01-06
CN103251562B (zh) 2016-04-27
CN1798545B (zh) 2013-06-05
EP1633327B1 (de) 2010-08-11
PL1633327T3 (pl) 2011-02-28
HK1086202A1 (en) 2006-09-15
JP4987474B2 (ja) 2012-07-25
DK1633327T3 (da) 2010-11-15
JP2012121885A (ja) 2012-06-28
ATE476964T1 (de) 2010-08-15
PT1633327E (pt) 2010-11-08
CA2528411C (en) 2012-09-04
EP1633327A1 (de) 2006-03-15
EP1633327A4 (de) 2009-03-04
WO2005000271A1 (en) 2005-01-06
JP2006526658A (ja) 2006-11-24
CA2528411A1 (en) 2005-01-06
ES2350485T3 (es) 2011-01-24

Similar Documents

Publication Publication Date Title
DE602004028610D1 (de) Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen
WO2007058776A3 (en) Hepatocyte growth factor intron fusion proteins
ATE252601T1 (de) Lang wirkende insulinotrope peptide
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
FI971406A0 (fi) TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
ATE345387T1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
DE69331832T2 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
FI963277A0 (fi) Paramuunisuusinduktori, joka perustuu rokkoviruskomponenttien yhdistelmiin, menetelmä sen valmistamiseksi ja sen käyttö lääkeaineena
ATE405296T1 (de) Blut- pool kontrastmittel zur verwendung in der magnetischen resonanzs-diagnostik
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
BRPI0518636B8 (pt) “kits não-radioativo liofilizado de multi-doses, e, processo para a preparação de múltiplas doses de paciente unitárias do radiofarmacêutico tetrofosmina- 99m tc"
ATE251634T1 (de) Chirale phosphorierte ligande brauchbar in katalysatoren
KR100313064B1 (ko) C-키트수용체의리간드및그의사용방법
BR0110892A (pt) Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos
FI982745A (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt"
CA2373252A1 (en) Long lasting anti-angiogenic peptides
WO2001008708A3 (en) Enhanced delivery via serpin enzyme complex receptor ligands
HUP0203195A2 (hu) Redox reverzibilis HCV-fehérjék natívhoz hasonló konformációval
JPS59181223A (ja) インタ−フエロンの安定化法
FI880027A (fi) Antibakteriellt lyofiliserat preparat.
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
Burris et al. Palliative treatment of accessible solid tumors with intratumoral cisplatin/epinephrine injectable gel
NO894682D0 (no) Liggeunderlag til bruk i sykeseng for pasienter med liggesaar, brannsaar eller lignende.